Dr Ashleys Limited (DRAS) and Impact BioMedical Inc. (IBO) have signed a merger and share exchange agreement.
Upon closing, Dr Ashleys Limited will acquire Impact BioMedical through a reverse merger.
The combined entity will be traded on the NYSE American under the name Dr Ashleys Limited.
Frank D. Heuszel, CEO of Impact BioMedical, expressed excitement about joining forces with Dr Ashleys Limited.
He highlighted that their global reach and financial strength will support bringing innovations to market, benefiting people worldwide.
